![]() Net loss was only $5.9 million, a substantial improvement from the $19.2 million loss in the same period of the prior year. The increase was caused primarily by increased head count. Operating expenses jumped substantially in the quarter, coming in at $42.5 million, up 69% year over year. Gross margin for Nevro jumped to 66% in the second quarter, a strong improvement from the 52% that was reported in the same period a year ago. ![]() ![]() and $14.8 million in international markets. That revenue breakdown was $40.6 million in sales in the U.S. Revenue grew to $55.4 million, which was up a huge 385% over the year-ago period. So what: It was a productive quarter for Nevro. EDT in response to a strong second-quarter earnings report. (NYSE: NVRO), a medical device company focused on chronic pain, are up 13% as of 11:50 a.m.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |